Maha H. Hussain, MB ChB, whose work has helped advance treatment and care of men with prostate cancer, was honored in the Genitourinary Cancer category with a 2015 Giants of Cancer Care® award, a program that the Intellisphere® Oncology Specialty Group launched to recognize leaders in the field.
Although it has been nearly 10 years since a new systemic drug has been approved for the treatment of patients with hepatocellular carcinoma, the field is changing rapidly due to new therapies for a prime underlying cause of the disease and advances in interventional radiology.
Discussions with patients must carefully consider the understandable desire of patients for definitive and hopeful information while at the same time appreciating that poorly understood biology often makes definitive statements and declarations regarding prognosis problematic and not infrequently incorrect.
A collection of clinical trials that uses a target-specific and tissue-agnostic algorithm to rapidly match patients to investigational therapies aimed at the tumor's molecular makeup takes the approach that "one trial really does not fit all."
There’s no question that checkpoint
blockade immunotherapy agents,
most notably those directed at the
PD-1/PD-L1 pathway, will continue to
grow in importance as an anticancer
modality in a rising number of tumor